Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 13.74B P/E 41.42 EPS this Y -14.20% Ern Qtrly Grth -98.60%
Income 798.86M Forward P/E 7.90 EPS next Y 13.20% 50D Avg Chg -3.00%
Sales 2.24B PEG 2.29 EPS past 5Y 38.07% 200D Avg Chg -16.00%
Dividend 2.00% Price/Book 2.31 EPS next 5Y 3.20% 52W High Chg -31.00%
Recommedations 2.00 Quick Ratio 12.48 Shares Outstanding 452.11M 52W Low Chg 5.00%
Insider Own 13.41% ROA 3.54% Shares Float 388.77M Beta 0.46
Inst Own 71.95% ROE 12.06% Shares Shorted/Prior 16.90M/13.25M Price 30.65
Gross Margin 54.19% Profit Margin 35.69% Avg. Volume 2,432,067 Target Price 44.83
Oper. Margin -12.99% Earnings Date May 9 Volume 1,837,290 Change -0.81%
About Royalty Pharma plc

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Royalty Pharma plc News
07/24/24 Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital
07/21/24 Royalty Pharma (NASDAQ:RPRX) Is Due To Pay A Dividend Of $0.21
07/19/24 Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024
07/17/24 Royalty Pharma Declares Third Quarter 2024 Dividend
07/02/24 Is Royalty Pharma plc (RPRX) a Good Stock to Buy Now?
06/22/24 Royalty Pharma plc (NASDAQ:RPRX) is largely controlled by institutional shareholders who own 70% of the company
06/04/24 Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
05/28/24 Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
05/22/24 Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
05/22/24 Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
05/13/24 Royalty Pharma to Present at Upcoming Investor Conferences
05/12/24 Here's What Analysts Are Forecasting For Royalty Pharma plc (NASDAQ:RPRX) After Its First-Quarter Results
05/11/24 Only Four Days Left To Cash In On Royalty Pharma's (NASDAQ:RPRX) Dividend
05/10/24 Royalty Pharma PLC (RPRX): A Strategic SWOT Insight
05/09/24 Royalty Pharma Reports First Quarter 2024 Results
05/09/24 Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
05/04/24 Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be $0.21
04/20/24 Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21
04/19/24 Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
04/17/24 Royalty Pharma Declares Second Quarter 2024 Dividend
RPRX Chatroom

User Image SanKish Posted - 14 minutes ago

$RPRX Why did this drop after hours? Any news we missed?

User Image Stock_Titan Posted - 5 days ago

$RPRX Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024 https://www.stocktitan.net/news/RPRX/royalty-pharma-to-announce-second-quarter-2024-financial-results-on-pgzgt6jtdlar.html

User Image Stocksrunner Posted - 1 week ago

After-Hours Breakout Alert: $FSLY $GOOG $HSY $HUM $RPRX These stocks have crossed above their 200-day moving averages, signaling potential bullish momentum. Keep an eye on these names for possible continued upside. https://stocksrunner.com/technical

User Image PZFLY Posted - 1 week ago

$RPRX Terrible option activity on this one. Many strike prices with no bids at all.

User Image UncleStock Posted - 1 week ago

$RPRX $ZTS $JNJ $OGN suggested for $DRG US ARCA Pharmaceutical - value screen: https://zpr.io/tykPs

User Image Stockjewru Posted - 1 week ago

$RPRX only days this stock is up is when the rest of the market is down 🤔

User Image PZFLY Posted - 1 week ago

$RPRX Morgan Stanley just raised their price target on $RPRX to $51. Has to be some value there.

User Image Jasooon Posted - 1 week ago

$EXAS $RPRX $BDSX - rate cuts are cominggggg https://x.com/kobeissiletter/status/1811378373911789665?s=46&t=7vIazpOiaR63N_ccf3b54A

User Image ViktorSinclair Posted - 2 weeks ago

$RPRX Management has to go. All of them. Total disaster of a company.

User Image sa_trader Posted - 2 weeks ago

$RPRX Volume dried up, 285K volume so far. Weak hands are shaken out, should reverse from here.

User Image UncleStock Posted - 2 weeks ago

$RPRX $ZTS $JNJ $OGN suggested for $DRG US ARCA Pharmaceutical - value screen: https://zpr.io/tykPs

User Image Capitulation_0 Posted - 2 weeks ago

$RPRX Picking some up here..

User Image Jasooon Posted - 2 weeks ago

$RPRX https://x.com/adamfeuerstein/status/1810265591720091697?s=46&t=7vIazpOiaR63N_ccf3b54A

User Image EagleMan1 Posted - 2 weeks ago

$EYEN $SXTC and $RPRX and $OGN and $SNDL What is new and opportunity in $EYEN? The stock is $EYEN. ==> fair value 11.09 1 - Insider bought 1.5 million shares in July and paid 1 Million dollars 2 - Vanguard biggest institution in the world bought 5 million dollars for a call option 3 - First FDA MydCombi selling from April 2024, and they have a contract with Vision Source biggest Private Practice Optometrists in the USA and Canada. Vision Source multi a billion company. 4 - Second FDA's strongest eyedrop sales start the first of August and are expected to generate 15 to 40 million per quarter. 5 - 8 or 9 August earnings call, and it should be good. 6 - MicroPine and MicroLine are unmet need eyedrops for children and the result is coming in Q4 2024.

User Image sa_trader Posted - 2 weeks ago

$RPRX Added today. Volume dried up, should bounce from here.

User Image ForestFoxes Posted - 3 weeks ago

$ANVS volume at 1.124M right now (Avg. Vol. 532.1K). Not particularly huge since this morning's Phase 3 Parkinson's drug study data release. It was trending pre-Market and still now with TSLA switching placing on Stocktwits first and second position. I'm surprised ANVS is still trending right next to TSLA (which is first right at this moment). Cost to Borrow rate is a relatively (for this stock!) low 108.16% w/ 10,000 available remaining shares to borrow. Tomorrow should be interesting. Most interesting will be what the FDA says, which is likely in Sept. or thereafter. If Annovis gains support in one form or another from a BP or $RPRX then that's full confirmation in my opinion. https://www.royaltypharma.com The timing is excellent with the anticipated passage of the "National Plan to End Parkinson's Act".

User Image 366157_38884773 Posted - 3 weeks ago

$RPRX The numbers seem solid but why is there such a high short interest against this stock? Can we expect a short squeeze soon?

User Image UncleStock Posted - 1 month ago

$RPRX $ZTS $JNJ $OGN suggested for $DRG US ARCA Pharmaceutical - value screen: https://zpr.io/tykPs

User Image SanKish Posted - 1 month ago

@Batman9988 if RSI mattered then there are lots of stocks with RSI in the oversold stage (like $KEY $RPRX $DIS etc). Why are the investors not talking about them? I blame the lazy investors who just want to ride the selected few tech stocks and then complain when their puts on those don’t work. There are many good companies with lower RSI outside of tech. We just need to do the research and diversify. That does not mean sell off good tech stocks. But stay away from overbought overblown PE stocks for few months.

User Image SanKish Posted - 1 month ago

@Reversalbuzz what are thoughts with the recent price action for $RPRX ? When ER is good, analysts are projecting higher TPs then why is this stuck at 27-28?

User Image SanKish Posted - 1 month ago

$RPRX Why is this not moving up when all analysts claim this is a strong buy? Are they manipulating?

User Image UncleStock Posted - 1 month ago

$RPRX $ZTS $JNJ $OGN suggested for $DRG US ARCA Pharmaceutical - value screen: https://zpr.io/tykPs

User Image Ss7415 Posted - 1 month ago

@WarrenPsnik a nice deal with $RPRX would be nice.

User Image RiskVsReward Posted - 1 month ago

$RPRX Check this out guys, potentially an interesting set up here. 💲

User Image Reversalbuzz Posted - 1 month ago

$RPRX entry 27.49 targets 28.87 30.26

User Image NIVOLOCO Posted - 1 month ago

$SBFM $NVAX $PFE $RPRX

User Image Stock_Titan Posted - 1 month ago

$RPRX Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes https://www.stocktitan.net/news/RPRX/royalty-pharma-announces-pricing-of-1-5-billion-of-senior-unsecured-h4fnl3h16b37.html

User Image Jasooon Posted - 1 month ago

$RPRX https://x.com/bowtiedbiotech/status/1796869142349230299?s=46&t=7vIazpOiaR63N_ccf3b54A

User Image cristhm Posted - 05/31/24

$RPRX just opened a position here... wish us luck 🙏

User Image fda_tracker Posted - 05/29/24

$RPRX New PDUFA Date 2024-08-20 Royalty Pharma plc Link:https://www.globenewswire.com/news-release/2024/05/28/2888905/0/en/Royalty-Pharma-and-Agios-Pharmaceuticals-Enter-Into-Vorasidenib-Royalty-Agreement-for-905-Million.html Calendar:http://www.fdatracker.com/fda-calendar/

Analyst Ratings
Morgan Stanley Overweight Jul 11, 24
UBS Neutral Jun 3, 24
B of A Securities Buy Apr 12, 24
JP Morgan Overweight Feb 20, 24
Goldman Sachs Buy Feb 20, 24
Morgan Stanley Overweight Nov 9, 23
Morgan Stanley Overweight Oct 11, 23
Morgan Stanley Overweight Aug 9, 23
Morgan Stanley Overweight Jul 11, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
RIGGS RORY B Director Director Jan 02 Sell 27.95 470,000 13,136,500 20,099 01/04/24
Avara Management Ltd 10% Owner 10% Owner Dec 27 Sell 28.11 251,592 7,072,251 2,543,323 12/29/23
Coyne Terrance P. EVP & CFO EVP & CFO Aug 09 Sell 30.73 75,000 2,304,750 790,000 08/11/23
Coyne Terrance P. EVP & CFO EVP & CFO Jul 12 Sell 31 75,000 2,325,000 865,000 07/14/23
Lloyd George W. EVP, Investments & C.. EVP, Investments & CLO Jun 02 Sell 33.63 192,221 6,464,392 30,000 06/06/23
Legorreta Pablo G. CEO, Chairman of the.. CEO, Chairman of the Board May 24 Buy 32.2496 150,000 4,837,440 380,000 05/24/23
RIGGS RORY B Director Director May 22 Sell 32.82 1,750,000 57,435,000 6,762 05/22/23
RIGGS RORY B Director Director Mar 29 Sell 36.6 139,950 5,122,170 1,456,762 03/30/23
Lloyd George W. EVP, Investments & C.. EVP, Investments & CLO Mar 28 Sell 37.04 112,779 4,177,334 212,221 03/30/23
Lloyd George W. EVP, Investments & C.. EVP, Investments & CLO Feb 23 Sell 37.2663 25,000 931,658 325,000 02/27/23
Urist Marshall EVP, Research & Inve.. EVP, Research & Investments Feb 22 Sell 37.2965 23,333 870,239 46,667 02/24/23
RIGGS RORY B Director Director Dec 09 Sell 42.02 60,000 2,521,200 96,712 12/13/22
Coyne Terrance P. EVP & CFO EVP & CFO Nov 02 Sell 43.0629 5,500 236,846 964,500 11/04/22
Giuliani Mario Germano Director Director Sep 28 Sell 41.05 32,593 1,337,943 8,077,140 09/30/22
Giuliani Mario Germano Director Director Sep 22 Sell 41.1681 211,380 8,702,113 8,109,733 09/26/22
GG 1978 SICAF SIF S.A. - GG St... 10% Owner 10% Owner Sep 20 Sell 41.0201 267,815 10,985,798 21,426,170 09/22/22
Giuliani Mario Germano Director Director Sep 16 Sell 41.61 387,171 16,110,185 22,657,815 09/20/22
GG 1978 SICAF SIF S.A. - GG St... 10% Owner 10% Owner Sep 16 Sell 41.61 387,171 16,110,185 21,693,985 09/20/22
RIGGS RORY B Director Director Sep 14 Sell 42.31 100,000 4,231,000 276,712 09/15/22
Giuliani Mario Germano Director Director Sep 07 Sell 42.7 499,500 21,328,650 8,577,140 09/09/22
GG 1978 SICAF SIF S.A. - GG St... 10% Owner 10% Owner Sep 07 Sell 42.7 498,006 21,264,856 22,426,170 09/09/22
GG 1978 SICAF SIF S.A. - GG St... 10% Owner 10% Owner Aug 25 Sell 44 1,994 87,736 22,924,176 08/29/22
Giuliani Mario Germano Director Director Aug 25 Sell 44 500 22,000 9,076,640 08/29/22
RIGGS RORY B Director Director Aug 09 Sell 43.7294 45,000 1,967,823 376,712 08/11/22
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Aug 09 Sell 43.92 20,854 915,908 201,114 08/11/22
Coyne Terrance P. EVP & CFO EVP & CFO Aug 01 Sell 43.1909 30,000 1,295,727 970,000 08/03/22
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Jul 28 Sell 43.9676 4,046 177,893 221,968 08/01/22
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Jul 25 Sell 43.28 75,100 3,250,328 226,014 07/27/22
Urist Marshall EVP, Research & Inve.. EVP, Research & Investments Jul 25 Sell 43.12 23,334 1,006,162 07/27/22
RIGGS RORY B Director Director Jun 29 Sell 42.1746 30,000 1,265,238 421,712 06/29/22
Urist Marshall EVP, Research & Inve.. EVP, Research & Investments Jun 24 Sell 43.1875 23,333 1,007,694 23,334 06/24/22
Reddoch James F. EVP & Chief Scientif.. EVP & Chief Scientific Officer Jun 08 Sell 41.559 100,000 4,155,900 920,800 06/10/22
Reddoch James F. EVP & Chief Scientif.. EVP & Chief Scientific Officer May 27 Sell 41.0801 75,000 3,081,008 1,020,800 05/31/22
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC May 26 Sell 40.49 100,000 4,049,000 430,000 05/31/22
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC May 23 Sell 40.2677 100,000 4,026,770 530,000 05/25/22
Urist Marshall EVP, Research & Inve.. EVP, Research & Investments May 16 Sell 39.8507 23,333 929,836 46,667 05/16/22
RIGGS RORY B Director Director Mar 29 Sell 38.5887 60,000 2,315,322 601,712 03/30/22
RIGGS RORY B Director Director Mar 17 Sell 39.33 169,089 6,650,270 03/21/22
Fernandez Henry A Director Director Feb 24 Buy 37.4884 32,500 1,218,373 58,200 02/25/22
RIGGS RORY B Director Director Dec 28 Sell 40.16 184,448 7,407,432 592,748 12/30/21
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Nov 16 Sell 42.51 250,000 10,627,500 630,000 11/18/21
RIGGS RORY B Director Director Nov 16 Sell 42.28 214,389 9,064,367 1,115,645 11/18/21
RIGGS RORY B Director Director Jun 29 Sell 42.17 1,314,912 55,449,839 3,451,258 06/29/21
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Jun 14 Sell 46.47 70,000 3,252,900 240,000 06/14/21
Urist Marshall EVP & Co-Head of R&I EVP & Co-Head of R&I Jun 08 Sell 46.08 33,134 1,526,815 06/08/21
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Jun 04 Sell 42.11 62,500 2,631,875 1,050,000 06/04/21
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Apr 16 Sell 42.13 69,822 2,941,601 200,000 04/16/21
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Apr 14 Sell 42.32 449 19,002 255,898 04/14/21
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Mar 04 Sell 47.37 125,000 5,921,250 300,000 03/04/21
Reddoch James F. EVP, Research & Inve.. EVP, Research & Investments Mar 04 Sell 47.37 100,000 4,737,000 300,000 03/04/21